PT  - JOURNAL ARTICLE
AU  - Servando Hernandez Vargas
AU  - Sukhen C. Ghosh
AU  - Ali Azhdarinia
TI  - New Developments in Dual-Labeled Molecular Imaging Agents
AID  - 10.2967/jnumed.118.213488
DP  - 2019 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 459--465
VI  - 60
IP  - 4
4099  - http://jnm.snmjournals.org/content/60/4/459.short
4100  - http://jnm.snmjournals.org/content/60/4/459.full
SO  - J Nucl Med2019 Apr 01; 60
AB  - Intraoperative detection of tumors has had a profound impact on how cancer surgery is performed and addresses critical unmet needs in surgical oncology. Tumor deposits, margins, and residual cancer can be imaged through the use of fluorescent contrast agents during surgical procedures to complement visual and tactile guidance. The combination of fluorescent and nuclear contrast into a multimodality agent builds on these capabilities by adding quantitative, noninvasive nuclear imaging capabilities to intraoperative imaging. This review focuses on new strategies for the development and evaluation of targeted dual-labeled molecular imaging agents while highlighting the successful first-in-human application of this technique.